JP2020158505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020158505A5 JP2020158505A5 JP2020079093A JP2020079093A JP2020158505A5 JP 2020158505 A5 JP2020158505 A5 JP 2020158505A5 JP 2020079093 A JP2020079093 A JP 2020079093A JP 2020079093 A JP2020079093 A JP 2020079093A JP 2020158505 A5 JP2020158505 A5 JP 2020158505A5
- Authority
- JP
- Japan
- Prior art keywords
- lyophilized composition
- nhl
- lymphoma
- seq
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 27
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 12
- 210000003719 b-lymphocyte Anatomy 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 229940127121 immunoconjugate Drugs 0.000 claims 7
- 239000007788 liquid Substances 0.000 claims 7
- 230000002062 proliferating effect Effects 0.000 claims 7
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- 239000000872 buffer Substances 0.000 claims 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- 230000000306 recurrent effect Effects 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 229940074404 sodium succinate Drugs 0.000 claims 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical group [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 2
- 239000008227 sterile water for injection Substances 0.000 claims 2
- 239000008362 succinate buffer Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 125000000185 sucrose group Chemical group 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000010922 relapsed/refractory diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021171589A JP7585177B2 (ja) | 2018-04-13 | 2021-10-20 | 安定した抗ｃｄ７９ｂ免疫複合体製剤 |
| JP2024194712A JP2025032097A (ja) | 2018-04-13 | 2024-11-06 | 安定した抗ｃｄ７９ｂ免疫複合体製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862657185P | 2018-04-13 | 2018-04-13 | |
| US62/657,185 | 2018-04-13 | ||
| JP2019076133A JP6761506B2 (ja) | 2018-04-13 | 2019-04-12 | 安定した抗ｃｄ７９ｂイムノコンジュゲート製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019076133A Division JP6761506B2 (ja) | 2018-04-13 | 2019-04-12 | 安定した抗ｃｄ７９ｂイムノコンジュゲート製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021171589A Division JP7585177B2 (ja) | 2018-04-13 | 2021-10-20 | 安定した抗ｃｄ７９ｂ免疫複合体製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020158505A JP2020158505A (ja) | 2020-10-01 |
| JP6965395B2 JP6965395B2 (ja) | 2021-11-10 |
| JP2020158505A5 true JP2020158505A5 (enExample) | 2021-11-11 |
Family
ID=68161211
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019076133A Active JP6761506B2 (ja) | 2018-04-13 | 2019-04-12 | 安定した抗ｃｄ７９ｂイムノコンジュゲート製剤 |
| JP2020079093A Active JP6965395B2 (ja) | 2018-04-13 | 2020-04-28 | 安定した抗ｃｄ７９ｂ免疫複合体製剤 |
| JP2021171589A Active JP7585177B2 (ja) | 2018-04-13 | 2021-10-20 | 安定した抗ｃｄ７９ｂ免疫複合体製剤 |
| JP2024194712A Pending JP2025032097A (ja) | 2018-04-13 | 2024-11-06 | 安定した抗ｃｄ７９ｂ免疫複合体製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019076133A Active JP6761506B2 (ja) | 2018-04-13 | 2019-04-12 | 安定した抗ｃｄ７９ｂイムノコンジュゲート製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021171589A Active JP7585177B2 (ja) | 2018-04-13 | 2021-10-20 | 安定した抗ｃｄ７９ｂ免疫複合体製剤 |
| JP2024194712A Pending JP2025032097A (ja) | 2018-04-13 | 2024-11-06 | 安定した抗ｃｄ７９ｂ免疫複合体製剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11648317B2 (enExample) |
| EP (1) | EP3773721A4 (enExample) |
| JP (4) | JP6761506B2 (enExample) |
| KR (1) | KR20210003147A (enExample) |
| CN (3) | CN112040981A (enExample) |
| AR (1) | AR114780A1 (enExample) |
| AU (1) | AU2019252941A1 (enExample) |
| CA (1) | CA3095186A1 (enExample) |
| CL (2) | CL2020002624A1 (enExample) |
| CR (2) | CR20250325A (enExample) |
| IL (1) | IL277943A (enExample) |
| MX (2) | MX2020010729A (enExample) |
| MY (1) | MY203529A (enExample) |
| PE (2) | PE20251257A1 (enExample) |
| TW (3) | TW202513095A (enExample) |
| UA (1) | UA128064C2 (enExample) |
| WO (1) | WO2019200322A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029869T2 (en) * | 2008-01-31 | 2017-04-28 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
| US20160082120A1 (en) | 2014-09-23 | 2016-03-24 | Genentech, Inc. | METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES |
| CR20250325A (es) * | 2018-04-13 | 2025-08-29 | Genentech Inc | Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550) |
| AU2018451747A1 (en) * | 2018-12-06 | 2021-06-17 | F. Hoffmann-La Roche Ag | Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody |
| TW202108178A (zh) * | 2019-05-14 | 2021-03-01 | 美商建南德克公司 | 使用抗CD79b免疫結合物治療濾泡性淋巴瘤之方法 |
| EP4045090A1 (en) * | 2019-10-18 | 2022-08-24 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
| EP4190812A4 (en) * | 2020-07-27 | 2024-09-04 | Tuojie Biotech (Shanghai) Co., Ltd. | ANTI-CD79B ANTIBODY-DRUG CONJUGATE, ITS PREPARATION METHOD AND ITS PHARMACEUTICAL USE |
| KR20240056587A (ko) * | 2021-09-16 | 2024-04-30 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 항-her3 항체 약물 접합체, 이의 조성물, 및 이의 용도 |
| MX2024009079A (es) * | 2022-01-26 | 2024-07-30 | Shanghai Mabgen Biotech Ltd | Composicion farmaceutica que comprende el conjugado anticuerpo anti-cd79b-farmaco y su uso. |
| US20250319167A1 (en) * | 2024-04-15 | 2025-10-16 | DiaMedica Therapeutics, Inc. | Intravenous compositions of tissue kallikrein-1 and related methods |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3587657D1 (de) | 1984-01-30 | 1993-12-23 | Imp Cancer Res Tech | Verbesserungen an wachstumsfaktoren. |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| WO1991005264A1 (en) | 1989-09-29 | 1991-04-18 | Oncogenetics Partners | Detection and quantification of neu related proteins in the biological fluids of humans |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| CA2109861C (en) | 1992-12-04 | 1999-03-16 | Shu-Hui Chen | 6,7-modified paclitaxels |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| EP0616812B1 (en) | 1993-03-24 | 1999-11-03 | Berlex Biosciences | Combination with anti-hormonal compounds and binding molecules for the treatment of cancer |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| DK2275119T3 (da) | 1995-07-27 | 2013-11-11 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| EP2364997A3 (en) | 1999-01-15 | 2012-07-04 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
| MX336033B (es) * | 2005-08-03 | 2016-01-07 | Immunogen Inc | Formulaciones de inmunoconjugado. |
| ES2381788T3 (es) | 2007-07-16 | 2012-05-31 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
| HUE029869T2 (en) | 2008-01-31 | 2017-04-28 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
| CA3051090C (en) * | 2009-01-09 | 2022-04-12 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| US20130273098A1 (en) * | 2010-12-10 | 2013-10-17 | Jeffrey T. Blue | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions |
| PE20150614A1 (es) | 2012-07-09 | 2015-05-25 | Genentech Inc | Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina |
| MY181960A (en) * | 2013-05-02 | 2021-01-15 | Hoffmann La Roche | Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate |
| PT3071237T (pt) * | 2013-11-21 | 2024-08-26 | Genmab As | Formulação liofilizada de conjugados anticorpo-fármaco |
| JP2015209384A (ja) | 2014-04-24 | 2015-11-24 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 医薬製剤 |
| US20160082120A1 (en) * | 2014-09-23 | 2016-03-24 | Genentech, Inc. | METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES |
| CR20250325A (es) * | 2018-04-13 | 2025-08-29 | Genentech Inc | Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550) |
-
2018
- 2018-04-13 CR CR20250325A patent/CR20250325A/es unknown
-
2019
- 2019-04-12 WO PCT/US2019/027329 patent/WO2019200322A1/en not_active Ceased
- 2019-04-12 US US16/383,478 patent/US11648317B2/en active Active
- 2019-04-12 UA UAA202006479A patent/UA128064C2/uk unknown
- 2019-04-12 PE PE2025000551A patent/PE20251257A1/es unknown
- 2019-04-12 JP JP2019076133A patent/JP6761506B2/ja active Active
- 2019-04-12 AR ARP190100971A patent/AR114780A1/es unknown
- 2019-04-12 EP EP19785369.0A patent/EP3773721A4/en active Pending
- 2019-04-12 MX MX2020010729A patent/MX2020010729A/es unknown
- 2019-04-12 TW TW113121547A patent/TW202513095A/zh unknown
- 2019-04-12 CA CA3095186A patent/CA3095186A1/en active Pending
- 2019-04-12 TW TW108112935A patent/TWI811335B/zh active
- 2019-04-12 CN CN201980025490.1A patent/CN112040981A/zh active Pending
- 2019-04-12 CN CN202410751629.3A patent/CN118615457A/zh active Pending
- 2019-04-12 MY MYPI2020005286A patent/MY203529A/en unknown
- 2019-04-12 PE PE2020001583A patent/PE20201503A1/es unknown
- 2019-04-12 KR KR1020207032399A patent/KR20210003147A/ko not_active Ceased
- 2019-04-12 AU AU2019252941A patent/AU2019252941A1/en active Pending
- 2019-04-12 CN CN202110524346.1A patent/CN113384711A/zh active Pending
- 2019-04-12 CR CR20200550A patent/CR20200550A/es unknown
- 2019-04-12 TW TW112126392A patent/TWI848769B/zh active
-
2020
- 2020-04-28 JP JP2020079093A patent/JP6965395B2/ja active Active
- 2020-10-09 CL CL2020002624A patent/CL2020002624A1/es unknown
- 2020-10-09 MX MX2022014457A patent/MX2022014457A/es unknown
- 2020-10-11 IL IL277943A patent/IL277943A/en unknown
-
2021
- 2021-07-23 CL CL2021001956A patent/CL2021001956A1/es unknown
- 2021-10-20 JP JP2021171589A patent/JP7585177B2/ja active Active
-
2023
- 2023-04-07 US US18/297,553 patent/US20240325559A1/en active Pending
-
2024
- 2024-11-06 JP JP2024194712A patent/JP2025032097A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020158505A5 (enExample) | ||
| JP2024016177A5 (enExample) | ||
| JP2022119854A5 (enExample) | ||
| JP2022036932A5 (enExample) | ||
| US12435138B2 (en) | Immunotoxins, formulations thereof and their use in medicine | |
| RU2633509C2 (ru) | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения | |
| JP2019146572A5 (enExample) | ||
| US20220169705A1 (en) | Topical application for an anti-hsv antibody | |
| JP2018535648A5 (enExample) | ||
| RU2012131099A (ru) | Препарат антитела | |
| JP2021501214A5 (enExample) | ||
| RU2017107847A (ru) | Стабильный состав на основе антитела к il-4r-альфа | |
| JP2020518600A5 (enExample) | ||
| NO343797B1 (no) | Flytende farmasøytisk formulering inneholdende CD40-antistoff og anvendelse av slike. | |
| JP2016533335A5 (enExample) | ||
| JP2017534253A5 (enExample) | ||
| JP2017522861A5 (enExample) | ||
| RU2015111341A (ru) | Композиции антитела и белка | |
| PE20201503A1 (es) | Formulaciones de inmunoconjugado anti-cd79b estables | |
| JP2013531679A5 (enExample) | ||
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| JPWO2019023564A5 (enExample) | ||
| AR129062A1 (es) | Composiciones farmacéuticas de proteínas terapéuticas y métodos de uso | |
| AR126614A1 (es) | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma | |
| AU2023375894A1 (en) | Antigen binding molecules targeting sars-cov-2 |